Skip to main content
Download PDF

Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis

Arthritis Research & Therapy volume 21, Article number: 191 (2019) Cite this article

Abstract

Background

Lysophosphatidic acid (LPA), generated by autotaxin (ATX), is a bioactive lipid mediator that binds to the receptors (LPA1–6), and serves as an important mediator in inflammation. Previous studies have demonstrated that LPA-LPA1 cascade contributes to arthritis and skin sclerosis. In this study, we examined the role of LPA signals in murine Candida albicans water-soluble fraction (CAWS)-induced vasculitis.

Methods

ATX and LPA receptor expressions were analyzed by immunohistochemistry and quantitative reverse transcription-polymerase chain reaction. Effects of LPA1 inhibition on CAWS-induced vasculitis were evaluated in LPA1-deficient mice or using an LPA1 antagonist, LA-01. Migration activity was assessed using a chemotaxis chamber. The number of migrated fluorescently labeled neutrophils, which were transferred into the vasculitis mice, was counted in the aortic wall. CXCL1 and IL-8 concentrations were determined by enzyme-linked immunosorbent assay.

Results

ATX and LPA1 were highly expressed in the inflamed region of CAWS-induced vasculitis. Severity of the vasculitis in LPA1-deficient mice was suppressed. The LPA1 antagonist, LA-01, also ameliorated the CAWS-induced vasculitis. LPA induced neutrophil migration, which was inhibited by LA-01 in vitro. Infiltration of transferred neutrophils from LPA1-deficient mice into the coronary arteries was suppressed. LA-01 also inhibited the infiltration of wild-type neutrophils. Expression of CXCL1 and IL-8 in human endothelial cells was enhanced by LPA, but was inhibited by LA-01. ATX and LPA1 expression levels were higher in the affected skin region of vasculitis patients than in healthy controls.

Conclusions

These results suggest that LPA-LPA1 signaling contributes to the development of vasculitis via chemoattractant production from endothelial cells followed by neutrophil recruitment. Thus, LPA1 has potential as a novel target for vasculitis therapies.

Introduction

Systemic vasculitides are characterized by the infiltration of inflammatory leukocytes into blood vessels, which induces destructive damage to the structures of the vessels. The affected vessels vary in size, type, and location according to the type of vasculitic disease [1]. For example, anti-neutrophil cytoplasmic antibody-associated vasculitis is well known to affect small vessels, Kawasaki disease middle vessels, and giant cell arteritis large vessels [1,2,3]. Immune cells, including neutrophils, macrophages, and lymphocytes, infiltrate the vessel wall and promote chronic inflammation in vasculitis [4]. Neutrophils have been shown to play an important role in vasculitis [5, 6]. They are activated in the inflamed vessel wall and release proteases, cytokines, chemokines, and neutrophil extracellular traps [5, 7]. Therefore, interfering with the recruitment and activation of neutrophils in the vessel walls is an underappreciated target for vasculitis therapies.

Autotaxin (ATX), which exhibits lysophospholipase D activity, generates lysophosphatidic acid (LPA) via the hydrolysis of lysophosphatidylcholine. LPA is a bioactive lipid mediator that binds to a group of cell surface G protein-coupled receptors (LPA1–6) [8,9,10]. We previously demonstrated that LPA1 plays an essential role in the pathogenesis of murine collagen-induced arthritis [11]. We also found that the LPA-LPA1 cascade contributes to the migration of macrophages into inflamed joints, Th17 differentiation, osteoclastogenesis, and the activation of fibroblast-like synoviocytes from rheumatoid arthritis [11, 12]. Previous studies reported that LPA1 was strongly expressed in the skin tissue of scleroderma patients, and the abrogation of LPA1 ameliorated murine bleomycin-induced skin sclerosis [13]. However, the role of the LPA-LPA1 cascade in the activation of neutrophils currently remains unclear. Moreover, the effects of LPA1 inhibition on vasculitis have yet to be examined.

Severe coronary arteritis accompanied by neutrophil infiltration was developed in the experimental model of murine Candida albicans water-soluble fraction (CAWS)-induced vasculitis, which is considered to be an appropriate model of arteritis [14,15,16]. We and others previously showed that neutrophils and macrophages play important roles in CAWS-induced vasculitis [17, 18].

In the present study, we demonstrate that LPA-LPA1 signals are essential for the development of vasculitis via neutrophil migration and also that the abrogation of LPA1 ameliorated CAWS-induced vasculitis, suggesting that LPA1 is a promising therapeutic target for vasculitis.

Materials and methods

Induction of CAWS-induced vasculitis

CAWS was prepared from C. albicans strain NRBC1385 using a previously described method [19]. Six-week-old male C57/BL6 mice were purchased from Oriental Yeast. The original lines of LPA1-deficient mice [20] were backcrossed to the inbred C57BL/6 strain for at least 15 generations. We then used these mice as the C57BL/6 background. In order to induce vasculitis, CAWS (1 mg/mouse) was injected intraperitoneally into mice in a volume of 0.2 ml once daily from days 1 to 5. On day 28, the heart was harvested and examined. The experimental protocol for animal experiments was approved by the Institutional Animal Care and Use Committee of Tokyo Medical and Dental University.

Real-time reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was prepared from tissues including the aorta and coronary artery of CAWS-induced vasculitis and normal mice, and first-strand cDNA was synthesized. Quantitative real-time PCR was performed as described previously [21]. cDNA was amplified with primers for LPA1–6 and 18S ribosomal RNA (rRNA) as previously described [11]. 18S rRNA was used as an internal control in order to standardize the amount of sample mRNA, and the relative expression of real-time PCR products was determined.

Immunohistochemistry

Paraffin-embedded skin tissues (4-μm-thick sections) from CAWS-induced vasculitis mice, vasculitis patients, and healthy donors were deparaffinized, immersed in 1 mM EDTA at 99–100 °C for 20 min, removed from the heat, and left to stand at room temperature for 20 min, followed by rinsing with a mixture of Tris-buffered saline with Tween 20. Endogenous peroxidase activity was blocked by an incubation in 0.3% H2O2 for 30 min. Sections were then blocked with 1% skim milk for 45 min and stained with a rabbit anti-ATX polyclonal antibody (pAb) (2 μg/ml; Cayman Chemical), -LPA1 pAb (10 μg/ml: Lifespan Biosciences), or normal rabbit IgG (Sigma Aldrich) as an isotype control at room temperature for 45 min. Antibody binding was detected using the Envision kit (DakoCytomation) as described previously [11].

Treatment of CAWS-induced vasculitis with an LPA1 antagonist

Mice injected with CAWS were treated with an LPA1 antagonist (LA-01 [11, 12] provided by Ono Pharmacological; 200, 60 mg/kg/day, or vehicle) by oral gavage twice a day from days 0 to 28. On day 28, the fixed hearts were embedded in paraffin and sectioned. In order to observe histological changes in the coronary arteries and aorta in detail, step sections in a horizontal direction were prepared every 20 μm. Sections were stained with hematoxylin and eosin (H&E). In order to quantitatively evaluate vascular inflammation, each of the 5 areas (3 aortic root areas and both coronary arteries) was scored on a scale of 0–3 according to the classification system for the areas of cellular infiltration: (a) aortic root (score 0 for no inflammation; 1, cell infiltration < 100 μm in diameter; 2, 100–199 μm in diameter; 3, ≥ 200 μm in diameter) and (b) coronary arteries (score 0 for no inflammation; 1, cell infiltration < 50 μm in diameter; 2, 50–99 μm in diameter; 3, ≥ 100 μm in diameter). The severity of arteritis in each mouse was defined as the sum of the scores of the 5 segments (maximum possible score of 15).

In vitro chemotaxis assay of neutrophils

The Ly-6G-positive neutrophils of wild-type (WT) or LPA1-deficient mice were purified from spleen using MACS microbead-coupled mAbs and magnetic cell separation columns (Miltenyi Biotec) as previously described [17]. The purity of Ly-6G-positive cells was more than 95%. The purified neutrophils from WT mice were incubated with LA-01 (0, 1, and 10 nM) at 37 °C for 30 min in RPMI 1640 medium (Sigma-Aldrich). After being incubated, neutrophils were washed twice with RPMI 1640. Neutrophils (1 × 106 cells/well) were added to the upper well of the transwell with a 3.0-μm pore polycarbonate membrane insert (Corning), while LPA [1-Oleoyl LPA (Cayman Chemical)] (10 μM) was added to the lower wells, and then incubated at 37 °C for 2 h. The number of cells that migrated into the lower well was counted using the Accuri C6 Flow Cytometer (Accuri Cytometers). Triplicates of three independent experiments were performed.

Migration of neutrophils into inflamed vascular walls

Murine Ly6G-positive splenocytes were labeled with Cell Tracker Green CMFDA (5-chloromethylfluorescein diacetate) (Molecular Probes), according to the protocol supplied by the manufacturer, and previously described [17]. The labeled cells (1.0 × 107) were transferred into the tail vein of CAWS-induced vasculitis mice on day 21. Recipient mice were treated with LA-01 (100 mg/kg) or saline 12 h and 30 min before and 12 h after the transfer. Twenty-four hours after the transfer, the number of labeled cells in the synovium was counted under a fluorescent microscope (Biozero) as previously described [17].

Enzyme-linked immunosorbent assay (ELISA)

Human umbilical vein endothelial cells (HUVECs) were cultured overnight in 48-well plates (1 × 105 cells/well), then incubated with LA-01 (0, 0.2, 1, 10 nM) for 30 min before being stimulated with LPA (10 μM) in FCS-free endothelial growth basal medium-2 at 37 °C for 24 h. CXC chemokine ligand 1 (CXCL1) and IL-8 protein levels in the culture supernatant were assessed using ELISA kits (R&D Systems) according to the instructions supplied by the manufacturer.

Patient specimens

The skin tissues of affected lesions were obtained from active vasculitis patients [microscopic polyangiitis (MPA), n = 5; polyangiitis nodosa (PN), n = 3; eosinophilic granulomatosis with polyangiitis (EGPA), n = 1] who fulfilled diagnostic criteria by the Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan [22] as well as from healthy controls [n = 3]. Tissues were stained with ATX and LPA1 as described above. The experimental protocol was approved by the Ethics Committee of the Tokyo Medical University, and all subjects provided informed consent according to the Declaration of Helsinki principles.

Statistical analysis

Data are expressed as the mean ± SEM. A comparison of data from the two groups was conducted by the Student t test. P values less than 0.05 were considered to be significant.

Results

Expression of ATX and LPA receptors in murine CAWS-induced vasculitis

We analyzed the expression of ATX and the LPA receptors, LPA1–6, in murine CAWS-induced vasculitis using quantitative RT-PCR and immunohistochemistry. CAWS-injected mice showed inflammatory cell infiltration in the aortic root and coronary arteries [17]. The expression of ATX mRNA in the aorta and coronary arteries was significantly higher in CAWS-induced vasculitis mice than in control mice (Fig. 1a). The expression of each LPA receptor mRNA was compared between CAWS-induced vasculitis and control mice. The expression of LPA1 mRNA was increased in CAWS-induced vasculitis mice than in control mice (Fig. 1b). No significant differences were observed in the expression of LPA2–6 between CAWS-induced vasculitis and control mice. Immunohistochemical analysis revealed that ATX and LPA1 were highly expressed in infiltrated inflammatory cells in the aortic root and coronary arteries in CAWS-induced vasculitis mice than in control mice (Fig. 1c). These results suggest that the ATX-LPA-LPA1 cascade contributes to the pathogenesis of CAWS-induced vasculitis.

Fig. 1
figure1

Expression of ATX and LPA receptors in CAWS-induced vasculitis. a, b Expression levels of ATX (a) and LPA1–6 (b) mRNAs were compared between CAWS-induced vasculitis mice (n = 3) and control mice (n = 3) using real-time RT-PCR. Data are the mean ± SEM; *P < 0.05 vs OA. Data are derived from multiple samples. c The expression of ATX and LPA1 in the aorta of control mice and CAWS-induced vasculitis mice was analyzed by immunohistochemistry. Original magnification: × 100 (left and middle panel), × 400 (right panel)

Full size image

Inhibition of inflammatory cell infiltration into the vascular wall by the abrogation of LPA1

We next examined the role of LPA1 in the development of vasculitis using LPA1-deficient mice (Fig. 2a, b). LPA1-deficient mice were resistant to CAWS-induced vasculitis. Histologically, inflammatory cell infiltration was suppressed in the coronary arteries and aortic roots of LPA1-deficient mice, whereas abundant cellular infiltration was observed in WT mice.

Fig. 2
figure2

Inhibition of inflammatory cell infiltration into the vascular wall by the abrogation of LPA1. a, b C57/BL6 WT and LPA1-deficient mice were injected intraperitoneally with CAWS. The hearts of WT and LPA1-deficient mice (n = 10, each) were stained with H&E (a). Representative photomicrographs are shown. The vasculitis scores of WT and LPA1-deficient mice were evaluated (b). c, d C57/BL6 mice were injected intraperitoneally with CAWS from days 0 to 5. LA-01 (0, 60, 200 mg/kg/day; n = 10, each) was administered twice daily from days 0 to 28. On day 28, the hearts of mice were stained with H&E (c). Representative photomicrographs are shown. The vasculitis score was evaluated (d). Original magnification: × 40 (a, c). Data are the mean ± SEM. *P < 0.05 vs WT mice or vehicle (b, d)

Full size image

In order to examine the effects of the LPA1 inhibitor on vasculitis, we treated CAWS-induced vasculitis mice with LA-01 (LPA1 antagonist) (Fig. 2c, d). LA-01 reduced the vasculitis score of mice treated with CAWS in a dose-dependent manner. These results suggest that LPA1 plays important roles in the development of vasculitis and can be considered as a potential new therapeutic target.

LPA1 is essential for LPA-induced neutrophil migration

We next investigated the mechanism by which LPA drives vascular inflammation. We have previously shown that abundant neutrophils are infiltrating in the vascular wall in CAWS-induced vasculitis [17]. Therefore, we asked if LPA1 was important for LPA-induced neutrophil recruitment in vitro. Neutrophils were isolated from mouse spleen and stimulated with LPA (10 μM), which induced the migration of neutrophils in transwell chambers. This effect was remarkably suppressed by the treatment of LA-01 (Fig. 3a). In addition, the effect on neutrophil migration of LPA is abrogated in neutrophils derived from LPA1-deficient mice (Fig. 3b).

Fig. 3
figure3

LPA1 is essential for LPA-induced neutrophil migration. a Ly-6G-positive neutrophils from murine spleen were incubated with LA-01 (0, 1, 10 nM) at 37 °C for 30 min in RPMI 1640. Cells were added to the upper wells of the transwell, LPA (10 μM) was loaded into the lower wells, and cells were incubated at 37 °C for 2 h. b Ly-6G-positive neutrophils from the spleen of WT or LPA1-deficient mice were loaded into the upper wells, LPA (10 μM) was added to the lower wells of the transwell, and cells were incubated at 37 °C for 2 h. The number of neutrophils that migrated into the lower well was counted by flow cytometry. Triplicates of three independent experiments were performed. Data are mean ± SEM; *P < 0.05 vs vehicle or WT mice. c, d Fluorescence-labeled Ly-6G-positive neutrophils from the spleen of WT mice were transferred into CAWS-induced vasculitis WT mice on day 21. The recipient mice were treated with LA-01 (100 mg/kg) or saline as a control 12 h and 30 min before and 12 h after the transfer. Migrated labeled cells were evaluated histologically 24 h after the transfer (c), and the number of labeled cells that migrated into the vascular walls was counted (d). e, f Fluorescence-labeled Ly-6G-positive neutrophils from the spleen of LPA1-deficient or WT mice were transferred into WT vasculitis mice on day 21. Migrated labeled cells were evaluated histologically 24 h after the transfer (e), and the number of labeled cells that migrated into the vascular walls was counted under a fluorescent microscope (f). Arrows indicate migrated labeled cells. Original magnification × 200 (c, e). Data are the mean ± SEM; *P < 0.05 vs vehicle or WT mice (d, f)

Full size image

In order to determine the role of LPA1 on neutrophil recruitment in vivo, fluorescently labeled Ly-6G-positive neutrophils from WT mice were transferred intravenously into CAWS-induced vasculitis mice, and the number of labeled neutrophils that infiltrated the vascular walls was counted 24 h later. LA-01 (100 mg/kg) was administered 12 h and 30 min before and 12 h after the transfer. Although this short-term treatment of LA-01 did not ameliorate the vasculitis score, it suppressed de novo neutrophil migration into the inflamed vessels (Fig. 3c, d).

We also compared neutrophil recruitment into the vasculitis region between neutrophils derived from LPA1-deficient and WT mice. The number of migrated neutrophils derived from LPA1-deficient mice was lower than that from WT mice (Fig. 3e, f). These results indicate that the migration of neutrophils into inflamed vascular walls is dependent on LPA1.

Effects of LPA-LPA1 signals on chemokine production from vascular endothelial cells

During inflammatory processes, chemokines upregulated on the surface of activated endothelial cells are thought to promote neutrophil recruitment [23]. We next examined the effects of LPA-LPA1 signals on chemokine production from endothelial cells. A stimulation with LPA induced the production of IL-8 and CXCL1 by HUVECs, which are the key chemoattractants of neutrophils [24]. The upregulated production of IL-8 and CXCL1 from LPA-stimulated HUVECs was inhibited by LA-01 (Fig. 4a, b).

Fig. 4
figure4

Effects of LPA-LPA1 signals on chemokine production from vascular endothelial cells. a, b HUVECs were stimulated with LPA (10 μM) at 37 °C for 24 h after being incubated with LA-01 (0, 0.2, 1, 10 nM) for 30 min. The protein levels of CXCL1 (a) and IL-8 (b) in the culture supernatant were assessed by ELISA. Data are the mean ± SEM; *P < 0.05 vs LA-01 (0 nM)

Full size image

Expression of ATX and LPA1 in the skin region of vasculitis patients

To assess the clinical relevance of our observations, we further analyzed the expression of ATX and LPA1 in the skin region of vasculitis patients by immunohistochemical analysis. Although no inflammatory changes were detected in skin tissue from healthy donors, ATX was expressed in the epidermis and in scattered cells in the dermis. The expression of LPA1 in normal skin was minimal. In contrast, ATX and LPA1 were strongly expressed in inflammatory cells, which were located in the dermis of skin tissues derived from MPA, EGPA, and PN patients (Fig. 5).

Fig. 5
figure5

Expression of ATX and LPA1 in the skin region of vasculitis patients. The expression of ATX and LPA1 in the skin regions of vasculitis patients (MPA: n = 2, PN: n = 2, EGPA: n = 1) and healthy controls (n = 3) was analyzed by immunohistochemistry. Original magnification × 40

Full size image

Discussion

In the present study, we have demonstrated that ATX and LPA1 were strongly expressed in the heart tissues of CAWS-induced vasculitis mice as well as in skin samples from patients with vasculitis. In addition, inhibition of LPA1 ameliorated CAWS-induced vasculitis. LPA-LPA1 signals induced neutrophil migration in vitro and in vivo. LPA-LPA1 signals also upregulated chemoattractant production from endothelial cells. These results suggest that the LPA-LPA1 cascade plays important roles in the vascular inflammation via neutrophil recruitment.

We previously reported that neutrophils were necessary for the pathogenesis of CAWS-induced vasculitis [17]. In the present study, we demonstrated that LPA-LPA1 signals induced neutrophil migration in vitro as well as neutrophil recruitment into the inflamed vasculitis region in vivo. LPA also induced the production of CXCL1 and IL-8 in endothelial cells via LPA1. Thus, decreasing the production of CXCL1 and IL-8 in the inflamed vascular walls of CAWS-induced vasculitis by inhibiting LPA1 may also contribute to the suppression of neutrophil infiltration in vivo. However, the stimulation with LPA did not alter the production of reactive oxygen species or elastase by neutrophils in vitro (data not shown). Therefore, LPA-LPA1 signals may be direct and/or indirect inducers of neutrophil migration, but not neutrophil activation during vasculitis.

We reported that LPA1 contributed to Th17 cell differentiation and macrophage migration in type II collagen-induced arthritis [11]. T cells and macrophages have also been shown to accumulate in the vasculitis region of CAWS-induced vasculitis [17]. It has been shown that CAWS-injected mice had higher proportion of Th17 cells in the spleen, suggesting that an imbalance between regulatory T cell and Th17 may consequently lead to CAWS-induced vasculitis [18]. The LPA-LPA1 cascade may also contribute to the pathogenesis of vasculitis via Th17 cell differentiation and macrophage accumulation as well as neutrophil migration.

In the present study, we identified important roles for LPA1 in the inflammatory processes in CAWS-induced vasculitis. Although LPA2–6 were also expressed in the vasculitis region of CAWS-induced vasculitis mice, their roles in vasculitis currently remain unclear. Further studies are needed in order to determine the roles of LPA2–6 in the pathogenesis of vasculitis. ATX and LPA1 were also expressed in the affected regions of MPA, PN, and EGPA, as well as CAWS-induced vasculitis. The ATX-LPA-LPA1 cascade may also contribute to the pathogenesis of vasculitis in patients with MPA, PN, and EGPA. Our study clearly demonstrated that LPA-LPA1 pathway is important for the development of vasculitis in mouse and human, providing a rationale for the trial of new therapeutic strategy for vasculitis.

Conclusions

In conclusion, the results of the present study suggest that LPA promotes neutrophil migration into the inflamed vascular walls of CAWS-induced vasculitis via LPA1. We consider LPA1 targeting therapy, supported further by other drug discovery efforts targeting LPA receptors [25] to have potential for the treatment of patients with vasculitis.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

ATX:

Autotaxin

CAWS:

Candida albicans water-soluble fraction

CXCL1:

CXC chemokine ligand 1

EGPA:

Eosinophilic granulomatosis with polyangiitis

H&E:

Hematoxylin and eosin

HUVECs:

Human umbilical vein endothelial cells

LPA:

Lysophosphatidic acid

MPA:

Microscopic polyangiitis

pAb:

Polyclonal antibody

PN:

Polyarthritis nodosa

rRNA:

Ribosomal RNA

RT-PCR:

Reverse transcription-polymerase chain reaction

WT:

Wild type

References

  1. 1.

    Watts RA, Scott DG. Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol. 2009. 23; 429–43. Netherlands.

  2. 2.

    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.

    CAS  Article  Google Scholar 

  3. 3.

    Miyabe C, Miyabe Y, Strle K, Kim ND, Stone JH, Luster AD, Unizony S. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2017;76(5):898–905.

    CAS  Article  Google Scholar 

  4. 4.

    Jennette JC. Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis. Cleve Clin J Med. 2002;69(Suppl 2):SII33–8.

    PubMed  Google Scholar 

  5. 5.

    Grayson PC, Kaplan MJ. At the bench: neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol. 2016;99(2):253–64.

    Article  Google Scholar 

  6. 6.

    Németh T, Mócsai A. The role of neutrophils in autoimmune diseases. Immunol Lett. 2012;143(1):9–19.

    Article  Google Scholar 

  7. 7.

    Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, Grone HJ, Brinkmann V, Jenne DE. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.

    CAS  Article  Google Scholar 

  8. 8.

    Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol. 2004;15(5):477–89.

    CAS  Article  Google Scholar 

  9. 9.

    Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321–54.

    CAS  Article  Google Scholar 

  10. 10.

    Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014;171(15):3575–94.

    CAS  Article  Google Scholar 

  11. 11.

    Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, Yokoyama W, Nagai J, Jona M, Tokuhara Y, Ohkawa R, et al. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum. 2013;65(8):2037–47.

    CAS  Article  Google Scholar 

  12. 12.

    Miyabe Y, Miyabe C, Iwai Y, Yokoyama W, Sekine C, Sugimoto K, Harigai M, Miyasaka M, Miyasaka N, Nanki T. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade. Arthritis Res Ther. 2014;16(5):461.

    Article  Google Scholar 

  13. 13.

    Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011;63(5):1405–15.

    CAS  Article  Google Scholar 

  14. 14.

    Takahashi K, Oharaseki T, Wakayama M, Yokouchi Y, Naoe S, Murata H. Histopathological features of murine systemic vasculitis caused by Candida albicans extract--an animal model of Kawasaki disease. Inflamm Res. 2004;53(2):72–7.

    CAS  Article  Google Scholar 

  15. 15.

    Nagi-Miura N, Shingo Y, Adachi Y, Ishida-Okawara A, Oharaseki T, Takahashi K, Naoe S, Suzuki K, Ohno N. Induction of coronary arteritis with administration of CAWS (Candida albicans water-soluble fraction) depending on mouse strains. Immunopharmacol Immunotoxicol. 2004;26(4):527–43.

    Article  Google Scholar 

  16. 16.

    Kurihara K, Shingo Y, Miura NN, Horie S, Usui Y, Adachi Y, Yadomae T, Ohno N. Effect of CAWS, a mannoprotein-beta-glucan complex of Candida albicans, on leukocyte, endothelial cell, and platelet functions in vitro. Biol Pharm Bull. 2003;26(2):233–40.

    CAS  Article  Google Scholar 

  17. 17.

    Miyabe C, Miyabe Y, Miura NN, Takahashi K, Terashima Y, Toda E, Honda F, Morio T, Yamagata N, Ohno N, et al. Am80, a retinoic acid receptor agonist, ameliorates murine vasculitis through the suppression of neutrophil migration and activation. Arthritis Rheum. 2013;65(2):503–12.

    CAS  Article  Google Scholar 

  18. 18.

    Martinez HG, Quinones MP, Jimenez F, Estrada C, Clark KM, Suzuki K, Miura N, Ohno N, Ahuja SK, Ahuja SS. Important role of CCR2 in a murine model of coronary vasculitis. BMC Immunol. 2012;13:56.

    CAS  Article  Google Scholar 

  19. 19.

    Uchiyama M, Ohno N, Miura NN, Adachi Y, Aizawa MW, Tamura H, Tanaka S, Yadomae T. Chemical and immunochemical characterization of limulus factor G-activating substance of Candida spp. FEMS Immunol Med Microbiol. 1999;24(4):411–20.

    CAS  Article  Google Scholar 

  20. 20.

    Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A. 2000;97(24):13384–9.

    CAS  Article  Google Scholar 

  21. 21.

    Watanabe K, Penfold ME, Matsuda A, Ohyanagi N, Kaneko K, Miyabe Y, Matsumoto K, Schall TJ, Miyasaka N, Nanki T. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum. 2010;62(11):3211–20.

    CAS  Article  Google Scholar 

  22. 22.

    Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56(2):87–96.

    CAS  Article  Google Scholar 

  23. 23.

    Miyabe Y, Miyabe C, Murooka TT, Kim EY, Newton GA, Kim ND, Haribabu B, Luscinskas FW, Mempel TR, Luster AD. Complement C5a receptor is the key initiator of neutrophil adhesion igniting immune complex-induced arthritis. Sci Immunol. 2017;2(7). https://doi.org/10.1126/sciimmunol.aaj2195.

    Article  Google Scholar 

  24. 24.

    Jin L, Batra S, Douda DN, Palaniyar N, Jeyaseelan S. CXCL1 contributes to host defense in polymicrobial sepsis via modulating T cell and neutrophil functions. J Immunol. 2014;193(7):3549–58.

    CAS  Article  Google Scholar 

  25. 25.

    Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015;333(2):171–7.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported in part by the Japanese Ministry of Education, Global Center of Excellence (GCOE) Program, International Research Center for Molecular Science in Tooth and Bone Diseases, and Takeda Science Foundation. JC was supported by the NIH (NS084398).

Author information

Affiliations

  1. Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Chie Miyabe, Yoshishige Miyabe, Nobuyuki Miyasaka & Toshihiro Nanki

  2. Department of Dermatology, Tokyo Medical University, Tokyo, Japan

    Chie Miyabe & Ryoji Tsuboi

  3. Division of Molecular and Pharmacology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Jun Nagai & Hiroshi Ueda

  4. Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan

    Noriko N. Miura & Naohito Ohno

  5. Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA, USA

    Jerold Chun

  6. Interdisciplinary Program for Biomedical Sciences, Osaka University, Osaka, Japan

    Masayuki Miyasaka

  7. Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan

    Toshihiro Nanki

  8. Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan

    Toshihiro Nanki

Authors
  1. Chie Miyabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshishige Miyabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noriko N. Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naohito Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jerold Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryoji Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Miyasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nobuyuki Miyasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshihiro Nanki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CM participated in the design of the study, carried out the experiments and statistical analysis, and drafted the manuscript. YM assisted in carrying out the experiments and with manuscript preparation. NM and NO provided CAWS. RT collected the clinical materials and assisted in data interpretation and manuscript preparation. JN, JC, and HU provided LPA1-deficient mice and helped animal experiments. MM, NM, and TN conceived of the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Toshihiro Nanki.

Ethics declarations

Ethics approval

The experimental protocol for animal study was approved by the Institutional Animal Care and Use Committee of Tokyo Medical and Dental University. The experimental protocol for human study was approved by the Ethics Committee of the Tokyo Medical University, and all subjects provided informed consent according to the Declaration of Helsinki principles.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Miyabe, C., Miyabe, Y., Nagai, J. et al. Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis. Arthritis Res Ther 21, 191 (2019). https://doi.org/10.1186/s13075-019-1973-0

Download citation

Keywords

  • Vasculitis
  • Lipid mediator
  • Neutrophil
  • Chemokine

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us